Passive mode-locking and terahertz frequency comb generation in resonant-tunneling-diode oscillator

Optical frequency combs in the terahertz frequency range are long-awaited frequency standards for spectroscopy of molecules and high-speed wireless communications. However, a terahertz frequency comb based on a low-cost, energy-efficient, and room-temperature-operating device remains unavailable especially in the frequency range of 0.1 to 3 THz. In this paper, we show that the resonant-tunneling-diode (RTD) oscillator can be passively mode-locked by optical feedback and generate a terahertz frequency comb. The standard deviation of the spacing between the comb lines, i.e., the repetition frequency, is reduced to less than 420 mHz by applying external bias modulation. A simulation model successfully reproduces the mode-locking behavior by including the nonlinear capacitance of RTD and multiple optical feedback. Since the mode-locked RTD oscillator is a simple semiconductor device that operates at room temperature and covers the frequency range of 0.1 to 2 THz (potentially up to 3 THz), it can be used as a frequency standard for future terahertz sensing and wireless communications

Multi-institutional phase II study on the safety and efficacy of dynamic tumor tracking-stereotactic body radiotherapy for lung tumors

Background and purpose: This study aimed to evaluate the safety and efficacy of dynamic tumor tracking-stereotactic body radiotherapy (DTT-SBRT) for lung tumors. Materials and methods: Patients with cStage I primary lung cancer or metastatic lung cancer with an expected range of respiratory motion of ≥10 mm were eligible for the study. The prescribed dose was 50 Gy in four fractions. A gimbal-mounted linac was used for DTT-SBRT delivery. The primary endpoint was local control at 2 years. Results: Forty-eight patients from four institutions were enrolled in this study. Forty-two patients had primary non-small-cell lung cancer, and six had metastatic lung tumors. DTT-SBRT was delivered for 47 lesions in 47 patients with a median treatment time of 28 min per fraction. The median respiratory motion during the treatment was 13.7 mm (range: 4.5–28.1 mm). The motion-encompassing method was applied for the one remaining patient due to the poor correlation between the abdominal wall and tumor movement. The median follow-up period was 32.3 months, and the local control at 2 years was 95.2% (lower limit of the one-sided 85% confidence interval [CI]: 90.3%). The overall survival and progression-free survival at 2 years were 79.2% (95% CI: 64.7%–88.2%) and 75.0% (95% CI: 60.2%–85.0%), respectively. Grade 3 toxicity was observed in one patient (2.1%) with radiation pneumonitis. Grade 4 or 5 toxicity was not observed. Conclusion: DTT-SBRT achieved excellent local control with low incidences of severe toxicities in lung tumors with respiratory motion